RxDoctor Payments Data

Catherine Almazan, MD

Family Medicine · Pensacola, FLNPI 1548606262

Payments from drug & device makers

$3,389in general payments, 2019–2025

Across 232 payments — averaging $14.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$759
  • Novo Nordisk$564
  • Lilly USA, LLC$427
  • Pfizer$376
  • AstraZeneca$262
  • Amgen$167
  • plus $834 from 16 others

What the payments were for

  • Food & beverage$3,377100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,389 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$112,347
Medicare patients
402
Services billed
1,882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide90$148,767
OzempicSemaglutide59$111,772
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$87,819
EliquisApixaban39$60,070
JardianceEmpagliflozin44$46,628
FarxigaDapagliflozin Propanediol39$27,974
TrulicityDulaglutide13$24,334
MyrbetriqMirabegron13$17,823
Lurasidone Hcl12$13,651
Xigduo XrDapaglifloz Propaned/Metformin16$12,651
XareltoRivaroxaban15$10,427
Emgality PenGalcanezumab-Gnlm12$8,611
Gabapentin162$6,416
Atorvastatin Calcium397$5,303
Rosuvastatin Calcium293$4,616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$427$173,101103 claims
Novo NordiskOzempic$564$111,77259 claims
GSKTrelegy Ellipta$150$87,81959 claims
PfizerEliquis$376$60,07039 claims
Boehringer IngelheimJardiance$48$46,62844 claims
AstraZenecaFarxiga$262$27,97439 claims
Astellas Pharma US IncMyrbetriq$64$17,82313 claims
Johnson & JohnsonXarelto$28$10,42715 claims
AbbVieSynthroid$759$2,11332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →